


# Overview

- Background
- Hepatitis C treatment in prisons
  - Nurse-led model of care (NLMC)
  - Scoping project
- Surveillance and Treatment of Prisoners with hepatitis C (SToP-C)

# Background

- 80 million chronically infected with HCV globally
- High rates amongst PWID including prisoners
- Growing burden of disease
- Prevention challenging
- Prison = incarceration / prison  $\neq$  health care
- Predominantly short stay
- Frequent movements
- NSW: 11,000 inmates; 25,000 annually
- 93% male; 19% Indigenous
- Poor mental health; ~30% chronic HCV



# HCV prevention in NSW prisons

No preventative  
vaccine



## Hepatitis C Incidence and Transmission Study in prisons (HITS-p)

- 49% reported injecting drug use in follow-up
- 31% reported sharing apparatus
- HCV incidence – 14% per annum
- No apparent protection from 'always' bleach cleansing or OST



No needle and  
syringe programs

*Luciani F. et al. Addiction 2014*

# Nurse-led model of care (NLMC)

- Goal: Increase HCV treatment rates in NSW prisons


Boonwaat et al *Med J Aust* 2010; 192 (9): 496-500

- NLMC pilot: (2009-2010)
  - Skills-based training of Clinical Nurse Consultants (CNCs)
  - Protocol driven nurse assessment and triage
  - Specialist reviews via telemedicine
  - Three centres - Lithgow, Goulburn, Long Bay
  - Qualitative and quantitative evaluation
- Safe, efficient, acceptable

Lloyd A et al *Clin Infect Dis* 2013 Apr;56(8):1078-84

# NLMC roll-out – NHMRC Partnership Project

CNSs / CNCs



Post-test counselling: chronic HCV

Protocol-driven investigations incl. Fibroscan

Focused history and examination / targeted mental health assessment

**Category A:**

Case discussion  
without patient

**Category B:**

Teleconference  
with patient

**Category C:**

Face-to-face  
review

Prescription

Antiviral therapy incl. triple

Post-treatment follow-up


# Triage decision

Category	Risk of medical or psychiatric complications on treatment	Motivation and psycho-social issues	Additional considerations	Action
<b>A</b>	Low risk, as there are no apparent medical or psychiatric conditions on history or current evaluation	Well-motivated and no psycho-social obstacles to successful completion of treatment and follow-up.	Stable circumstances in the correctional centre; good personal skills and social support structures.	Work up as per protocol and present to specialist (without the patient) for consideration for treatment.
<b>B</b>	Generally low risk of adverse events on treatment, but there are medical or psychiatric co-morbidities evident, such as a history of psychosis or possible auto-immune disease.	Well-motivated, but some issues requiring additional support and surveillance, such as ongoing injecting drug use or mental health concerns.	Generally stable circumstances in the correctional centre, but other concerns such as limited personal skills or social support structures.	Provide care plan addressing the individual's issues of concern, and arrange telephone consultation with specialist and patient.
<b>C</b>	Significant risk of serious adverse events on treatment, as there are pre-existing medical and/or psychiatric co-morbidities which are likely to impact upon antiviral treatment, such as advanced liver disease, HIV-co-infection, or current major depression.	Motivated, but has psycho-social issues, which are likely to impact upon treatment, such as active injecting drug use or a risk of deliberate self-harm.	To consider treatment: stable circumstances in the correctional centre, reasonable personal skills and social support structures required.	Arrange face-to-face consult with specialist physician. Additional investigations (e.g. exercise stress test) and specialist consultations (e.g. psychiatrist) likely to be required.


**Slides removed - until publication**

# Patient characteristics

Genotype distribution




Fibrosis stage (Fibroscan)





# CNC / CNS hepatitis training program

## Knowledge and skills-based training



*Accredited with University of Technology Sydney (UTS)*

# Scoping project

## Prisoners in Australia, 30/6/2013

	<b>Total Prisoners</b>	<b>Median age (years)</b>	<b>ATSI (%)</b>	<b>Median sentence length (years)</b>	<b>Remand (% of prisoners)</b>	<b>Remand (median time, months)</b>	<b>Prior adult imprisonment (%)</b>	<b>Current strategy HCV services</b>
<b>NSW</b>	9,897	34.2	23	3.6	28	3.3	55	✓
<b>VIC</b>	5,340	35.3	7	3.3	18	2.7	51	✓
<b>QLD</b>	6,076	32.9	31	3.0	22	3.5	65	✓
<b>SA</b>	2,266	35.9	22	4.5	34	2.3	51	✗
<b>WA</b>	4,924	33.3	40	2.5	20	2.4	62	✓
<b>TAS</b>	483	32.7	15	2.0	24	1.5	65	✗
<b>NT</b>	1,436	32.6	86	1.3	25	1.2	71	✗
<b>ACT</b>	353	31.2	18	2.8	26	1.4	73	✓


# Scoping project

## Prisons and health care personnel

	Total number of prisons	Number of prisons with hepatitis services	Specialist physician - prison based	Specialist physician - hospital based	Hepatitis nurse	General nurse	GP	Psychiatrist	Psychologist	Mental health nurse	D&A counsellor
<b>NSW</b>	31	31	✓	✓	✓	✓	✓	✓	✓	✓	✓
<b>VIC</b>	14	3	✓	✓	✓	✓	✓	✓	x	✓	✓
<b>QLD</b>	11	8	✓	✓	✓	✓	✓	✓	x	✓	x
<b>SA</b>	8	8	x	✓	✓	✓	✓	✓	x	✓	x
<b>WA</b>	16	9	x	✓	✓	✓	✓	x	✓	✓	✓
<b>TAS</b>	7	7	✓	✓	x	✓	x	x	x	x	x
<b>NT</b>	5	3	x	✓	✓	✓	✓	x	x	x	✓
<b>ACT</b>	2	2	✓	✓	✓	✓	✓	✓	x	x	x


*Mina M. et al. International Journal of Prisoner Health 2015 (in press)*

# HCV testing & treatment in prisons



# Scoping project


*How could hepatitis services be improved*



## Goals

- To evaluate the impact of rapid scale-up of DAA treatment on incidence and prevalence of HCV infection in the prison setting
- To develop a translational framework for subsequent establishment of treatment-as-prevention programs in the prison sector

# Study design



## Primary end-point:

- Reduction in HCV incidence in cohort across 4 SToP-C prisons

## Additional aims:

### *Mathematical modelling*

- Treatment sample size and epidemiological impact

### *Cost-effectiveness and budget impact*

- Is DAA therapy in prisons good value for money and can we afford it?

### *Qualitative evaluation*

- Patient & provider attitudes & barriers towards DAA therapy in prisons

### *Implementation toolkit*

- How can DAA therapy be scaled up in prisons across NSW and nationally?

# SToP-C network

**Lithgow Correctional Centre**  
Lithgow



**Outer Metropolitan Multipurpose Correctional Centre**  
Sydney



**Dillwynia (Womens) Correctional Centre**  
Sydney




**Goulburn Correctional Centre**  
Goulburn





# Current status – surveillance phase (at 10 Sep 2015)



Goulburn Correctional Centre

304

78

Lithgow Correctional Centre

55

0

**TOTAL**

**359**

**78**

## Treatment phase - 2016

- All prisoners with HCV infection eligible
- 12-week directly acting antiviral (DAA) therapy (sofosbuvir/velpatasvir)
- One fixed-dose tablet once daily
- >90% cure rates for Gt1-6
- Minimal side-effects
- Monitor re-infection rates and re-treat



# Education and promotion

- Prison staff (custodial & health) information sessions
- Resources for prisoners and family
  - Video
  - Posters
  - Booklet



**HEP C TESTS**

**IT'S QUICK, EASY, CONFIDENTIAL.**  
To test for hep C the nurse will collect a blood sample. The result will be ready in a couple of weeks and tell you if you have ever come into contact with the hep C virus and if you have the virus now.

**THERE ARE TWO BLOOD TESTS:**

An antibody test tells you if you have **EVER** come into contact with the hep C virus.

A PCR test tells you if you are infected with the virus **NOW**.

**Ab<sup>+</sup> + PCR<sup>+</sup> = You are infected with hep C NOW**

**Ab<sup>+</sup> + PCR<sup>-</sup> = You have been infected with hep C in the PAST but do not have it now**

**Ab<sup>-</sup> + PCR<sup>+</sup> = You have NEVER been infected with hep C**

**Ab<sup>-</sup> + PCR<sup>-</sup> = You have NEVER been infected with hep C**

**“Hepa” + “itis”**

means liver + means inflammation

So “Hepatitis” just means INFLAMMATION (damage) of the LIVER. Like “appendicitis” means inflammation of the appendix.

**GET TESTED STOP HEP C**

**QUICK - EASY - CONFIDENTIAL**

“I felt fine, but I just wanted to be sure I was in the clear. I got tested, and now I know where I stand.”

**LOTS OF PEOPLE IN PRISON HAVE HEP C**

Outside: 1 in 100 Australians have chronic hep C.

Inside: 30 in 100 inmates have chronic hep C.

1 in 8 inmates without hep C get infected each year if they inject.

**S | T | O | P | C**

THIS STUDY HAS BEEN APPROVED BY THE JUSTICE HEALTH HUMAN RESEARCH ETHICS COMMITTEE TO FIND OUT ABOUT THE STUDY BREAK WITH THE STOP-C RESEARCH NURSE.

# Project partners, stakeholders, funders



Justice  
Corrective Services



Health  
Justice Health &  
Forensic Mental Health Network



Health

